Annapaola Prestia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7124603/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	1.8	11
2	Prediction of AD dementia by biomarkers following the NIAâ€AA andÂIWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.4	71
3	Occipital sources of resting-state alpha rhythms are related to local gray matter density in subjects with amnesic mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2015, 36, 556-570.	1.5	93
4	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). Neurology, 2015, 84, 508-515.	1.5	122
5	Hippocampal and Amygdalar Local Structural Differences in Elderly Patients with Schizophrenia. American Journal of Geriatric Psychiatry, 2015, 23, 47-58.	0.6	19
6	Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. Alzheimer Disease and Associated Disorders, 2015, 29, 101-109.	0.6	14
7	A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia. Neuroinformatics, 2014, 12, 575-593.	1.5	240
8	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimer's and Dementia, 2013, 9, 677-686.	0.4	51
9	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.5	161
10	The in vivo topography of cortical changes in healthy aging and prodromal Alzheimer's disease. Supplements To Clinical Neurophysiology, 2013, 62, 67-80.	2.1	8
11	Summary Metrics to Assess Alzheimer Disease–Related Hypometabolic Pattern with ¹⁸ F-FDG PET: Head-to-Head Comparison. Journal of Nuclear Medicine, 2012, 53, 592-600.	2.8	79
12	Distinct cerebrospinal fluid amyloidâ€beta peptide signatures in cognitive decline associated with <scp>A</scp> lzheimer's disease and schizophrenia. Electrophoresis, 2012, 33, 3738-3744.	1.3	34
13	Cortical Changes in Incipient Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 22, 1339-1349.	1.2	18
14	Hippocampal and amygdalar volume changes in elderly patients with Alzheimer's disease and schizophrenia. Psychiatry Research - Neuroimaging, 2011, 192, 77-83.	0.9	38
15	Alzheimer's CSF markers in older schizophrenia patients. International Journal of Geriatric Psychiatry, 2011, 26, 640-648.	1.3	27
16	Alzheimer's disease and schizophrenia: evidence of a specific, shared molecular background. Future Neurology, 2011, 6, 17-21.	0.9	4
17	In vivo mapping of incremental cortical atrophy from incipient to overt Alzheimer's disease. Journal of Neurology, 2009, 256, 916-924.	1.8	116
18	In Vivo Neuropathology of Cortical Changes in Elderly Persons with Schizophrenia. Biological Psychiatry, 2009, 66, 578-585.	0.7	18

#	Article	IF	CITATIONS
19	Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimer's and Dementia, 2009, 5, 307-317.	0.4	80
20	Resting EEG sources correlate with attentional span in mild cognitive impairment and Alzheimer's disease. European Journal of Neuroscience, 2007, 25, 3742-3757.	1.2	101
21	Validation Study of the Three-Objects-Three-Places Test: A Screening Test for Alzheimer's Disease. Experimental Aging Research, 2006, 32, 395-410.	0.6	14